Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo tackles liver cancer after first drug fails

NCT ID NCT01840592

First seen May 07, 2026 · Last updated May 17, 2026 · Updated 2 times

Summary

This study tests whether adding a chemotherapy drug (doxorubicin) to the targeted therapy sorafenib can help people with advanced liver cancer whose disease got worse on sorafenib alone. About 30 adults with confirmed liver cancer and mild or no cirrhosis will receive the combination. The goal is to see if the combo improves survival and slows tumor growth, while monitoring side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Cancer Center at Basking Ridge

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center at Mercy Medical Center

    Rockville Centre, New York, 11570, United States

  • Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center

    Sleepy Hollow, New York, 10591, United States

  • Memorial Sloan Kettering West Harrison

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.